Title
Comorbid depression in medical diseases
Date Issued
01 December 2020
Access level
metadata only access
Resource Type
review
Author(s)
Gold S.M.
Köhler-Forsberg O.
Moss-Morris R.
Mehnert A.
Bullinger M.
Steptoe A.
Whooley M.A.
Otte C.
CRÓNICAS, Centro de Excelencia en Enfermedades Crónicas
Publisher(s)
Nature Research
Abstract
Depression is one of the most common comorbidities of many chronic medical diseases including cancer and cardiovascular, metabolic, inflammatory and neurological disorders. Indeed, the prevalence of depression in these patient groups is often substantially higher than in the general population, and depression accounts for a substantial part of the psychosocial burden of these disorders. Many factors can contribute to the occurrence of comorbid depression, such as shared genetic factors, converging biological pathways, social factors, health behaviours and psychological factors. Diagnosis of depression in patients with a medical disorder can be particularly challenging owing to symptomatic overlap. Although pharmacological and psychological treatments can be effective, adjustments may need to be made for patients with a comorbid medical disorder. In addition, symptoms or treatments of medical disorders may interfere with the treatment of depression. Conversely, symptoms of depression may decrease adherence to treatment of both disorders. Thus, comprehensive treatment plans are necessary to optimize care.
Volume
6
Issue
1
Language
English
OCDE Knowledge area
Políticas de salud, Servicios de salud
Scopus EID
2-s2.0-85089701205
PubMed ID
Source
Nature Reviews Disease Primers
ISSN of the container
2056676X
Sponsor(s)
S.M.G. receives funding from the Deutsche Forschungsgemeinschaft (GO1357/5-2; 8-2), the European Commission (IMI2 859366), the German Federal Ministry of Health (BMG-BVA 2520FSB431) and the National MS Society (MB-1707-28359; RG-1507-05418). J.J.M. has received support from the Alliance for Health Policy and Systems Research (HQHSR1206660), the Bernard Lown Scholars in Cardiovascular Health Program at Harvard T.H. Chan School of Public Health (BLSCHP-1902), Bloomberg Philanthropies, FONDECYT via CIENCIACTIVA/CONCYTEC, British Council, British Embassy and the Newton-Paulet Fund (223-2018, 224-2018), DFID/MRC/Wellcome Global Health Trials (MR/ M007405/1), Fogarty International Center (R21TW009982, D71TW010877), Grand Challenges Canada (0335-04), Inter-American Institute for Global Change Research (IAI CRN3036), International Development Research Center Canada (IDRC 106887, 108167), Medical Research Council (MR/P008984/1, MR/P024408/1, MR/P02386X/1), National Cancer Institute (1P20CA217231), National Heart, Lung and Blood Institute (HHSN268200900033C, 5U01HL114180, 1UM1HL134590), National Institute of Mental Health (1U19MH098780), Swiss National Science Foundation (40P740-160366), Wellcome Trust (074833/Z/04/Z, 093541/Z/10/Z, 103994/Z/14/Z, 107435/Z/15/Z, 205177/Z/16/Z, 214185/Z/18/Z, 218743/Z/19/Z) and the World Diabetes Foundation (WDF15-1224). C.O. has received funding from the Deutsche Forschungsgemeinschaft (OT 209/7-3; 14-1), the European Commission (IMI2 859366) and the German Federal Ministry of Education and Research (KS2017-067). The authors thank V. Stiglbauer (Charité – Universitätsmedizin Berlin) for help with formatting of the manuscript draft.
Sources of information:
Directorio de Producción Científica
Scopus